In a research report issued today, Cantor analyst Mara Goldstein maintained a Buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) with a $33 price …
In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a …
In a research report issued today, Cowen analyst Boris Peaker reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a $26 price target. …
Cowen analyst Boris Peaker maintained an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a price target of $26, following the news that the …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $43 price target, as the company announced the initiation of …
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and increased his price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $35 price …
In a research report released today, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a $36 price target, …
Roth Capital analyst Joseph Pantginis reiterated Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $40 price target, as Celldex and Oncothyreon (NASDAQ:ONTY) have initiated a Phase Ib …
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a price target of $35.00, following the company’s third-quarter financial …
